<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909025</url>
  </required_header>
  <id_info>
    <org_study_id>GM-IMAB-001</org_study_id>
    <nct_id>NCT00909025</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer</brief_title>
  <official_title>Clinical First-in-human Single-dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-center, Phase I, Open-label, i.v. Infusion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ganymed Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal&#xD;
      adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill&#xD;
      cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular&#xD;
      cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of&#xD;
      this phase I study is to establish safety, toxicity and maximal tolerable dose of a single&#xD;
      infusion of claudiximab in patients suffering from relapsing, advanced gastroesophageal and&#xD;
      gastric adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of maximum tolerated dose of claudiximab (Phase I: toxicities as assessed by NCI CTCAE version 3.0)</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the safety profile</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall tumor response as assessed by RECIST</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of antitumoral efficacy</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Claudiximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Claudiximab</intervention_name>
    <description>Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.&#xD;
After completion of study treatment, patients are followed for 4 weeks.</description>
    <arm_group_label>Claudiximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic, refractory or recurrent disease of advanced gastroesophageal cancer&#xD;
             (adenocarcinoma) proven by histology&#xD;
&#xD;
          -  CLDN18.2 expression confirmed by immunohistochemistry&#xD;
&#xD;
          -  Prior standard chemotherapy containing a fluoropyrimidine, a platinum compound and/or&#xD;
             epirubicine, and - if clinically appropriate - docetaxel&#xD;
&#xD;
          -  At least 1 measurable site of the disease according RECIST criteria (CT-scans or MRT&#xD;
             not older than 6 weeks before study entry)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 or Karnofsky Index 70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dl&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Prior allergic reaction or intolerance to a monoclonal antibody&#xD;
&#xD;
          -  Prior inclusion in the present study&#xD;
&#xD;
          -  Less than 3 weeks since prior anti-tumor or radiation therapy&#xD;
&#xD;
          -  Other investigational agents or devices concurrently or within 4 weeks prior to this&#xD;
             study&#xD;
&#xD;
          -  Other concurrent anticancer therapies&#xD;
&#xD;
          -  History of positive test for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  Known Hepatitis.&#xD;
&#xD;
          -  Uncontrolled or severe illness.&#xD;
&#xD;
          -  Concurrent administration of anticoagulation agents with vitamin K antagonists&#xD;
&#xD;
          -  Concurrent administration of therapeutic doses of heparin (prophylactic doses are&#xD;
             acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schuler, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innere Klinik (Tumorforschung) Universitätsklinikum Essen Hufelandstr. 55 45122 Essen, GERMANY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Innere Klinik (Tumorforschung)</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piejuras Hospital</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins University</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

